First-Line Antibiotic for Adult Lower Extremity Cellulitis Requiring Admission
For adults with lower extremity cellulitis requiring hospital admission, initiate intravenous vancomycin (or another agent effective against both MRSA and streptococci) if the patient has systemic signs of infection (SIRS), purulent drainage, penetrating trauma, evidence of MRSA infection elsewhere, MRSA nasal colonization, or injection drug use; otherwise, use an anti-streptococcal agent such as cefazolin. 1
Risk Stratification Determines Antibiotic Choice
The IDSA 2014 guidelines provide a clear algorithmic approach based on infection severity and risk factors 1:
For Severe Nonpurulent Cellulitis (with SIRS or high MRSA risk):
- Vancomycin is the recommended first-line agent
- Alternative: Any antimicrobial effective against both MRSA and streptococci
- This applies when patients have:
- Systemic inflammatory response syndrome (SIRS)
- Penetrating trauma
- Evidence of MRSA infection elsewhere
- MRSA nasal colonization
- Injection drug use
- Purulent drainage
For Moderate Nonpurulent Cellulitis (systemic signs without above risk factors):
- Anti-streptococcal coverage is essential
- Many clinicians appropriately include MSSA coverage
- Cefazolin 2g IV twice daily is highly effective 2
- In one study of 124 patients, cefazolin achieved 84.7% treatment success with only 15.3% re-admission rates 2
For Severely Compromised Patients:
- Vancomycin plus piperacillin-tazobactam OR vancomycin plus imipenem-meropenem
- This provides broad-spectrum coverage for polymicrobial or resistant organisms 1
Treatment Duration and Monitoring
- Recommended duration: 5 days minimum, but extend if infection has not improved 1
- Mean duration in successful outpatient IV therapy was 6.24 days 2
Critical Pitfalls to Avoid
Chronic venous disease (CVD) significantly increases treatment failure risk. In patients treated with cefazolin, 53% with CVD failed therapy versus only 18% without CVD (OR 4.4) 3. These patients require closer monitoring and may need earlier escalation of therapy.
Do not routinely culture blood or tissue in uncomplicated cases, but cultures are recommended when systemic signs are present 1. This helps guide de-escalation if MRSA coverage was initiated empirically.
Adjunctive Management
Beyond antibiotics, the guidelines emphasize 1:
- Elevation of the affected extremity
- Examine interdigital toe spaces carefully - treating tinea pedis (fissuring, scaling, maceration) reduces recurrence risk
- Address predisposing factors like edema and underlying skin disorders
Evidence Quality Note
The IDSA guideline 1 provides strong, moderate-quality evidence for these recommendations. While newer agents like dalbavancin show promise for preventing admission 4, they are not established as first-line therapy for patients already requiring admission. The meta-analysis showing equivalence between beta-lactams and macrolides 5 is less relevant here, as it primarily addressed outpatient therapy and did not specifically examine hospitalized patients with severe disease requiring MRSA coverage.